Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis-Reference-Cited by-同舟云学术

Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis

Published:2020-02-02 Issue:4 Volume:50 Page:323-337
ISSN:0882-0139
Container-title:Immunological Investigations
language:en
Short-container-title:Immunological Investigations

Author:

Zhou Hao-Yue¹²,Guo Biao³,Lufumpa Eniya⁴,Li Xiao-Mei⁵,Chen Li-Hong⁶,Meng Xiang⁷,Li Bao-Zhu¹²^ORCID

Affiliation:

1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China

2. Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, Anhui, China

3. Department of Human Resource, The Second Affiliated Hospital of Anhui Medical University, Anhui, Hefei, China

4. Institute of Applied Health Research, University of Birmingham, Birmingham, UK

5. Department of Rheumatology & Immunology, Anhui Provincial Hospital, Anhui, Hefei, China

6. Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, China

7. School of Stomatology, Anhui Medical University, Hefei, Anhui, China

Funder

National Natural Science Foundation of China

the Grants for Scientific Research of BSKY from Anhui Medical University.

Publisher

Informa UK Limited

Subject

General Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/08820139.2020.1714650

Reference52 articles.

1. The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals

2. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials

3. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

4. Epidemiology and risk factors for IBD

5. Tofacitinib in ulcerative colitis

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines;Journal of Hospital Infection;2024-06

2. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines;Gut;2024-04-12

3. Profiling the colonic mucosal response to fecal microbiota transplantation identifies a role for GBP5 in colitis in humans and mice;Nature Communications;2024-03-26

4. The level of protein in the maternal murine diet modulates the facial appearance of the offspring via mTORC1 signaling;Nature Communications;2024-03-26

5. Recent advances in nanocarrier systems for ulcerative colitis: A new era of targeted therapy and biomarker integration;Journal of Drug Delivery Science and Technology;2024-03